Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer

BACKGROUND: * Numerous recent therapeutic advances have changed standard treatment options for patients with GI cancer. These include newer chemotherapeutic agents in addition to established proof of principle for anti-angiogenic agents. The burden of GI cancers is reflected by the presence of three GI cancer types in the top five causes of cancer mortality. Over 58,000 deaths yearly can be attributed to GI cancer. * While immune-based therapies in GI cancers are experimental at the current time, a gathering body of literature is suggestive of an enormous potential, either alone, or most likely in combination with standard chemotherapy. * Before immunotherapy can be combined with non-immune based treatment options we first need to investigate the effects of non-immune based therapies on immune responses (especially immune-evasive mechanisms) with cancer. * Commensal gut microbiota play an important role in colonic inflammation and colon cancer. The human gut flora consists of approximately 100 trillion microbial cells, which their disruption leads to many types of diseases including inflammatory bowel disease and colorectal cancer. Recent studies have shown that colon cancer patients as well other patients with gastrointestinal cancers have an altered gut flora when compared to healthy controls. As an example, intestinal microbiome has been shown to contribute to the start and progression of certain kinds of liver diseases such as NAFLD as well as end-stage liver diseases 2-4 Therefore, it is important to investigate further as to how the gut affects the patient's response to chemotherapy, other types of cancer therapy and to tumor growth in general. OBJECTIVES: To serve as an umbrella protocol to allow collection, storage and investigation of samples from patients with gastrointestinal (GI) cancers in support of Thoracic and GI Oncology Branch translational trials to develop new therapeutic agents and novel treatment approaches as well as new prognostic and diagnostic models. Also, to collect samples from patients with non-GI cancers for comparison. ELIGIBILITY: * Individuals undergoing evaluation for participation in NCI treatment protocols in the NCI intramural program with diagnosis of cancer. * 18 year of age or older. DESIGN: * Blood, tumor tissue or stool samples may be collected from consenting participants at the initial visit and/or at the time of visit to NIH, scheduled per other NIH protocols. * Analysis of participant's samples include but not limited to immune-monitoring, single cell sequencing, identifying of gene expression and generation of CAR-T cells. * Stool samples will be used to determine the intestinal microbiome.